866-997-4948(US-Canada Toll Free)

Dengue Vaccine Market: Contribution of NGOs for Better Vaccine Access Expected to Drive the Market in Lower Income Countries: Global Industry Analysis & Opportunity Assessment, 2017 - 2027

Published By :

Future Market Insights

Published Date : Mar 2017

Category :

Vaccines

No. of Pages : 98 Pages

Global dengue vaccine market revenue is expected to expand at a significant rate owing to a large unmet need

The first dengue vaccine, Dengvaxia (CYD-TDV) developed by Sanofi Pasteur is registered in 14 countries in the Latin America and Asia Pacific region. CYD-TDV vaccine is a live recombinant tetravalent dengue vaccine that is indicated as a 3 dose series of 0/6/12 month schedule. There are around five other vaccine candidates under evaluation in clinical trials, comprising other live-attenuated vaccines as well as subunit, DNA and purified inactivated vaccine candidates of which Takedas TAK-003 and Butantan Institute vaccine candidates are being evaluated in phase 3 clinical trials currently.

The global dengue vaccine market is estimated to be valued at nearly US$ 250 Mn in 2017 and is expected to expand at a 17.5% CAGR over the forecast period (2017-2027). The global dengue vaccine market is projected to be valued at more than US$ 1250 Mn by 2027.

Factors impacting the global dengue vaccine market

Growth of the global dengue vaccine market is mainly driven by rising burden of dengue fever in tropical regions, large unmet medical need for managing dengue burden, promising end stage vaccine pipeline, development of live attenuated tetravalent dengue vaccine, and expected local production of dengue vaccine in various countries. Other prominent factors driving revenue growth of the market are adoption/uptake of dengue vaccine by various countries in dengue endemic regions of Latin America and Asia Pacific and increased governmental interest to incorporate the vaccine in public immunisation programmes across various countries.

However, supply side infrastructure bottlenecks such as surveillance system, standardised diagnostics practice, and cold chain systems for storage of vaccine in resource constrained countries are the factors hampering the growth of the global dengue vaccine market.

Companies engaged in the development of dengue vaccine are employing strategies to incorporate dengue vaccine in public immunisation programmes and vaccines in clinical stage development are being tested for safety and efficacy in all age groups and different transmission settings.

Global Dengue Vaccine Market Attractiveness Analysis by End User, 2017 - 2027

Several governments are willing to incorporate dengue vaccine in public immunisation programmes given assured quality, safety and affordability of the vaccine in endemic countries

The Government Institutes segment is expected to dominate the global dengue vaccine market in revenue terms and the trend is projected to continue throughout the forecast period. The Government Institutes segment is estimated to account for 49.5% value share in 2017 and is projected to account for 51.9% share by the end of 2027. In terms of value, the Hospitals segment is anticipated to register a moderate CAGR of 17.3% during the forecast period. The NGOs segment is expected to remain the least attractive segment in the global dengue vaccine market in revenue terms with an attractiveness index of 0.7 over the forecast period. The NGOs segment is estimated to account for 22.5% value share in 2017 and is projected to account for 20.5% value share by the end of 2027. Analyst Viewpoint

Developing a vaccine that is effective in all age groups is expected to drive market revenue growth over the forecast period

Of late dengue vaccine candidates, which are in the late stage of development, are showing better clinical benefits in all age groups and have better dosing pattern. For instance, Takedas - Tak-003 dengue vaccine candidate has demonstrated acceptable safety and efficacy in different population groups with two doses (three months apart) of vaccine. Currently Dengvaxia is recommended in three doses at 0, 6, 12 months. Development of dengue vaccine that is effective for infants and children is expected to reduce the dengue burden and thereby create demand in the global dengue vaccine market.

Table Of Content
1. Executive Summary
2. Market Introduction

2.1. Market Taxonomy


3. Global Dengue Vaccine Market Analysis Scenario
3.1. Market Size (US$ Mn) and Forecast
3.1.1. Market Size and Y-o-Y Growth
3.2.2. Absolute $ Opportunity
3.2. Market Overview


4. Market Dynamics and USPs
4.1. Macro-economic Factors
4.2. Drivers
4.2.1. Supply Side
4.2.2. Demand Side
4.3. Restraints
4.4. Opportunity
4.5. Trends
4.6. Dengue Vaccine Research Pipeline Analysis
4.7. Global Dengue Vaccine Market: Funding Scenario
4.8. Global Dengue Vaccine Market: Dengue Epidemiology Analysis
4.9. Global Dengue Vaccine Market: Dengvaxia SWOT
4.10. Global Dengue Vaccine Market: Dengvaxia Promotional Activities
4.11.Global Dengue Vaccine Market: Dengvaxia Sales Channel Strategy
4.12. Global Dengue Vaccine Market: Dengvaxia Tier-Pricing by Region


5. Global Dengue Vaccine Opportunity Analysis and Forecasts, By End User
5.1. Introduction
5.2. Basis Point Share (BPS) Analysis By End User
5.3. Y-o-Y Growth Projections By End User
5.4. Market Value Forecast By End User, 2017-2027
5.4.1. Hospitals
5.4.2. Government Institutes
5.4.3. NGOs
5.5. Prominent Trends
5.5. Market Attractiveness By End User


6. Global Dengue Vaccine Opportunity Analysis and Forecasts, By Region
6.1. Basis Point Share (BPS) Analysis By Region
6.2. Y-o-Y Growth Projections By Region
6.3. Market Value Forecast By Region
6.3.1. Latin America
6.3.2. Asia Pacific
6.3.3. Middle East and Africa (MEA)
6.3.4. Rest of the World (RoW)
6.4. Market Attractiveness By Region


7. Latin America Dengue Vaccine Opportunity Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis By Country
7.1.2. Y-o-Y Growth Projections By Country
7.2. Market Value Forecast By, 2016-2026
7.3. Market Value Forecast By End User, 2016-2026
7.3.1. Hospitals
7.3.2. Government Institutes
7.3.3. NGOs
7.4. Market Value Forecast By Country, 2016-2026
7.4.1. Brazil
7.4.2. Mexico
7.4.3. Venezuela
7.4.4. Rest of Latin America
7.5. Market Attractiveness Analysis
7.5.1. By End User
7.5.2. By Country


8. Asia Pacific Dengue Vaccine Opportunity Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis By Country
8.1.2. Y-o-Y Growth Projections By Country
8.2. Market Value Forecast By, 2016-2026
8.3. Market Value Forecast By End User, 2016-2026
8.3.1. Hospitals
8.3.2. Government Institutes
8.3.3. NGOs
8.4. Market Value Forecast By Country, 2016-2026
8.4.1. Philippines
8.4.2. Indonesia
8.4.3. Malaysia
8.4.4. Thailand
8.4.5. Vietnam
8.4.6. India
8.4.7. Rest of Asia Pacific
8.5. Market Attractiveness Analysis
8.5.1. By End User
8.5.2. By Country


9. Middle East and Africa (MEA) Dengue Vaccine Opportunity Analysis and Forecast
9.1.Introduction
9.1.1. Basis Point Share (BPS) Analysis By Country
9.1.2. Y-o-Y Growth Projections By Country
9.2.Market Value Forecast By, 2016-2026
9.3.Market Value Forecast By End User, 2016-2026
9.3.1. Hospitals
9.3.2. Government Institutes
9.3.3. NGOs
9.4.Market Value Forecast By Country, 2016-2026
9.4.1. Africas
9.4.2. GCC Countries
9.5.Market Attractiveness Analysis
9.5.1. By End User
9.5.2. By Country


10. Rest of the World (RoW) Dengue Vaccine Opportunity Analysis and Forecast
11. Competition Landscape
11.1. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
11.1.1. Sanofi
11.1.2. Takeda Pharmaceutical Company Limited


12. Assumptions and Acronyms Used


13. Research Methodology

 

List of Table

Table 01: Global Dengue Vaccine Market Value (US$ Mn) Opportunity Analysis and Forecast By Region, 2016–2027
Table 02: Global Dengue Vaccine Market Value (US$ Mn) Opportunity  Analysis and Forecast By Region, 2016–2027
Table 03: Global Dengue Vaccine Market Value (US$ Mn) Analysis and Forecast By End User, 2016–2027
Table 04: Global Dengue Vaccine Market Value (US$ Mn) Analysis and Forecast By Region, 2016–2027
Table 05: Latin America Dengue Vaccine Market Value (US$ Mn) Opportunity Analysis and Forecast By Country, 2016–2027
Table 06: Latin America Dengue Vaccine Market Value (US$ Mn) Opportunity Analysis and Forecast By End User, 2016–2027
Table 07: Asia Pacific Dengue Vaccine Market Value (US$ Mn) Analysis and Forecast By Country, 2016–2027
Table 08: Asia Pacific Dengue Vaccine Market Value (US$ Mn) Analysis and Forecast By End User, 2016–2027
Table 09: MEA Dengue Vaccine Market Value (US$ Mn) Analysis and Forecast By Country, 2016–2027
Table 10: MEA Dengue Vaccine Market Value (US$ Mn) Analysis and Forecast By End User, 2016–2027
Table 11: MEA Dengue Vaccine Market Value (US$ Mn) Analysis and Forecast By End User, 2016–2027

List of Chart

Figure 01: Global Dengue Vaccine Market Value Share By, End User, 2017
Figure 02: Global Dengue Vaccine Market Value Share By, Region, 2017
Figure 03: Global Dengue Vaccine Market Value (US$ Mn) Forecast, 2016–2027 
Figure 04: Global Dengue Vaccine Market Absolute $ Opportunity, 2016–2027  
Figure 05: Global Dengue Vaccine Market Y-o-Y Growth, 2017–2027
Figure 06: Global Dengue Vaccine Market Share Analysis (%) By End User, 2017, 2027
Figure 07: Global Dengue Vaccine Market Y-o-Y Growth (%) By End User, 2017–2027 
Figure 08: Global Dengue Vaccine Market Absolute $ Opportunity (US$ Mn) By Hospitals Segment, 2016 – 2027
Figure 09: Global Dengue Vaccine Market Absolute $ Opportunity (US$ Mn) By ASC Segment, 2016 – 2027
Figure 10: Global Dengue Vaccine Market Absolute $ Opportunity (US$ Mn) By NGOs Segment, 2016 – 2027
Figure 11: Global Dengue Vaccine Market Attractiveness Analysis By End User, 2017–2027 
Figure 12: Global Dengue Vaccine Market Share Analysis (%) By Region, 2017, 2027
Figure 13: Global Dengue Vaccine Market Y-o-Y Growth (%) By Region, 2017–2027 
Figure 14: Latin America Dengue Vaccine Market Absolute $ Opportunity (US$ Mn), 2016 – 2027
Figure 15: Asia Pacific Dengue Vaccine Market Absolute $ Opportunity (US$ Mn), 2016 – 2027
Figure 16: MEA Dengue Vaccine Market Absolute $ Opportunity (US$ Mn), 2016 – 2027
Figure 17: Eastern Europe Dengue Vaccine Market Absolute $ Opportunity (US$ Mn), 2016 – 2027
Figure 18: Global Dengue Vaccine Market Attractiveness Analysis By Region, 2017–2027 
Figure 19: Latin America Dengue Vaccine Market Share Analysis (%) By Country, 2017, 2027
Figure 20: Latin America Dengue Vaccine Market Y-o-Y Growth (%) By Country, 2017–2027 
Figure 21: Brazil Dengue Vaccine Market Absolute $ Opportunity (US$ Mn), 2016 – 2027
Figure 22: Mexico Dengue Vaccine Market Absolute $ Opportunity (US$ Mn), 2016 – 2027
Figure 23: Venezuela Dengue Vaccine Market Absolute $ Opportunity (US$ Mn), 2016 – 2027
Figure 24: Rest of Latin America
Figure 25: Latin America Dengue Vaccine Market Attractiveness Analysis By Country, 2017 – 2027 
Figure 26: Latin America Dengue Vaccine Market Attractiveness Analysis By End User, 2017 – 2027 
Figure 27: Asia Pacific Dengue Vaccine Market Share Analysis (%) By Country, 2017, 2027
Figure 28: Asia Pacific Dengue Vaccine Market Y-o-Y Growth (%) By Country, 2016–2027 
Figure 29: Philippines Dengue Vaccine Market Absolute $ Opportunity (US$ Mn), 2016 – 2027
Figure 30: Indonesia Dengue Vaccine Market Absolute $ Opportunity (US$ Mn), 2016 – 2027
Figure 31: Malaysia Dengue Vaccine Market Absolute $ Opportunity (US$ Mn), 2016 – 2027
Figure 32: Thailand Dengue Vaccine Market Absolute $ Opportunity (US$ Mn), 2016 – 2027
Figure 33: Vietnam Dengue Vaccine Market Absolute $ Opportunity (US$ Mn), 2016 – 2027
Figure 34: India Dengue Vaccine Market Absolute $ Opportunity (US$ Mn), 2016 – 2027
Figure 35: Rest of Asia Pacific Dengue Vaccine Market Absolute $ Opportunity (US$ Mn), 2016 – 2027
Figure 36: Asia Pacific Dengue Vaccine Market Attractiveness Analysis By Country, 2017 – 2027 
Figure 37: Asia Pacific Dengue Vaccine Market Attractiveness Analysis By End User, 2017 – 2027 
Figure 38: MEA Dengue Vaccine Market Share Analysis (%) By Country, 2017, 2027
Figure 39: MEA Dengue Vaccine Market Y-o-Y Growth (%) By Country, 2017–2027 
Figure 40: Africas Dengue Vaccine Market Absolute $ Opportunity (US$ Mn), 2016 – 2027
Figure 41: GCC Countries Dengue Vaccine Market Absolute $ Opportunity (US$ Mn), 2016 – 2027
Figure 42: MEA Dengue Vaccine Market Attractiveness Analysis By Country, 2017 – 2027 
Figure 43: MEA Dengue Vaccine Market Attractiveness Analysis By End User, 2017 – 2027

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *